Vazyme(SH:688105) Shang Hai Zheng Quan Bao·2026-02-11 18:44Core Viewpoint - The company, Nanjing Novogene Bioinformatics Technology Co., Ltd., has announced its expected daily related transactions for 2026, amounting to RMB 14.90 million, which is based on its business needs and the actual transactions from 2025 [3][9]. Group 1: Daily Related Transactions Overview - The expected daily related transactions for 2026 are estimated at RMB 14.90 million, reflecting an increase from the actual transactions of RMB 2.98 million in 2025 [3][9]. - The 2025 daily related transactions were approved by the board and amounted to RMB 5.90 million, with actual transactions being significantly lower than the estimate [1][2]. Group 2: Approval Process - The approval process for the 2026 expected daily related transactions involved multiple meetings, including a review by the audit committee and independent directors, confirming that the transactions are fair and will not harm the company or its shareholders [4][5][6]. - The independent directors unanimously agreed that the expected transactions are necessary for daily operations and will not affect the company's independence or financial health [6][9]. Group 3: Related Parties and Transaction Details - The expected transactions will involve related parties, specifically Nanjing Dino Wei Hua Biotechnology Co., Ltd., and will include sales of products, provision of technical services, and procurement of goods [7][8]. - Pricing for these transactions will be based on market prices, industry practices, and mutual agreement between the parties involved [8]. Group 4: Impact on Company - The expected daily related transactions are deemed necessary for the company's operations and are structured to ensure fairness and mutual benefit, thereby safeguarding the interests of all shareholders [9].